StemRIM Inc
TSE:4599
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
StemRIM Inc
Other Current Assets
StemRIM Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
StemRIM Inc
TSE:4599
|
Other Current Assets
¥425.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Other Current Assets
¥395.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-2%
|
|
|
GNI Group Ltd
TSE:2160
|
Other Current Assets
¥928m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
19%
|
CAGR 10-Years
37%
|
|
|
PeptiDream Inc
TSE:4587
|
Other Current Assets
¥1.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
|
Takara Bio Inc
TSE:4974
|
Other Current Assets
¥1.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
4%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Other Current Assets
¥395.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
30%
|
|
StemRIM Inc
Glance View
StemRIM, Inc. engages in the research and development of regeneration inducing medicine. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 46 full-time employees. The company went IPO on 2019-08-09. The firm is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
See Also
What is StemRIM Inc's Other Current Assets?
Other Current Assets
425.2m
JPY
Based on the financial report for Jan 31, 2026, StemRIM Inc's Other Current Assets amounts to 425.2m JPY.
What is StemRIM Inc's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
12%
Over the last year, the Other Current Assets growth was -8%. The average annual Other Current Assets growth rates for StemRIM Inc have been 4% over the past three years , 12% over the past five years .
